-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94

Benzinga·11/03/2026 17:11:42
Listen to the news
Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $97 to $94.